Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

Allergan420 enrolled

Overview

This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.

Study Type

OBSERVATIONAL

Enrollment

420

Conditions

Urinary Bladder, Overactive

Interventions

onabotulinumtoxinABIOLOGICAL

onabotulinumtoxinA (BOTOX®)100 to 200 U

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with documented idiopathic OAB diagnosis * Patient was treated with 100-200U of BOTOX® for OAB * Urodynamics assessment within prior to first BOTOX® injection. Exclusion Criteria: * Patient had received botulinum toxin formulations other than BOTOX® in the bladder * Patient had symptoms of OAB associated with a neurological condition (eg, spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc).

Locations (3)

Regional Urology

Shreveport, Louisiana, United States

Chesapeake Urology Associates, LLC

Baltimore, Maryland, United States

Virginia Urology

Richmond, Virginia, United States

Outcomes

Primary Outcomes

Pre-BOTOX® Injection VE Cutoff-Ratios that Predict the Risk of CIC following Treatment with 100-200U of BOTOX®

VE was calculated as the ratio of voided volume to the total bladder capacity.

Time frame: Pre-BOTOX® Injection (Baseline)

Length of Time of CIC Use in Clinical Practice after Treatment with 100-200U BOTOX®

Time frame: 12 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.